locametz
novartis europharm limited - gozetotide - radionuklidno slikanje - diagnostični radiofarmacevtiki - to zdravilo je samo za diagnostično uporabo. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.
pluvicto
novartis europharm limited - lutetium (177lu) vipivotide tetraxetan - prostatic neoplazem, kastracija-odporne - terapevtski radiofarmacevtiki - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.
degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostatične neoplazme - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
kresflo 125 mikrogramov/vpih inhalacijska suspenzija pod tlakom
momaja s.r.o. - flutikazonpropionat - inhalacijska suspenzija pod tlakom - flutikazonpropionat 125 µg / 1 vpih - flutikazon
kresflo 250 mikrogramov/vpih inhalacijska suspenzija pod tlakom
momaja s.r.o. - flutikazonpropionat - inhalacijska suspenzija pod tlakom - flutikazonpropionat 250 µg / 1 vpih - flutikazon
farydak
pharmaand gmbh - brezvodni panobinostat laktat - multiple myeloma - antineoplastična sredstva - farydak, v kombinaciji z bortezomiba in deksametazon, je indicirano za zdravljenje odraslih bolnikov s ponovila in/ali ognjevarnih multipli mielom, ki so prejeli vsaj dve predhodno režimi, vključno z bortezomiba in imunomodulatorne agent. farydak, v kombinaciji z bortezomiba in deksametazon, je indicirano za zdravljenje odraslih bolnikov s ponovila in/ali ognjevarnih multipli mielom, ki so prejeli vsaj dve predhodno režimi, vključno z bortezomiba in imunomodulatorne agent.
xermelo
serb sas - telotristat etiprat - carcinoid tumor; neuroendocrine tumors - drugi proizvodi prebavnega trakta in metabolizma - xermelo je indicirano za zdravljenje driska sindrom karcinoid v kombinaciji z somatostatina analogne (ssa) terapija pri odraslih, neustrezno nadzira prp terapijo.
kalcipos 500 mg/800 i.e. žvečljive tablete
meda ab - holekalciferol (vitamin d3); kalcij - žvečljiva tableta - holekalciferol (vitamin d3) 800 i.e. / 1 tableta kalcij500 i.e. / 1 tableta; kalcij 500 i.e. / 1 tableta - kalcij, kombinacije z vitaminom d in/ali drugimi učinkovinami
kalcipos 500 mg/800 i.e. žvečljive tablete
meda ab - holekalciferol (vitamin d3); kalcij - žvečljiva tableta - holekalciferol (vitamin d3) 800 i.e. / 1 tableta kalcij500 i.e. / 1 tableta; kalcij 500 i.e. / 1 tableta - kalcij, kombinacije z vitaminom d in/ali drugimi učinkovinami
kalcipos 500 mg/800 i.e. žvečljive tablete
meda ab - holekalciferol (vitamin d3); kalcij - žvečljiva tableta - holekalciferol (vitamin d3) 800 i.e. / 1 tableta kalcij500 i.e. / 1 tableta; kalcij 500 i.e. / 1 tableta - kalcij, kombinacije z vitaminom d in/ali drugimi učinkovinami